PET imaging in patients with meningioma—report of the RANO/PET Group

Norbert Galldiks (1, 2, 3, 4) , Nathalie Albert (5) , Michael Sommerauer (6, 7) , Anca Grosu (8) , Ute Ganswindt (5) , Ian Law (9) , Matthias Preusser (10) , Emilie Le Rhun (11) , Michael Vogelbaum (12) , Gelareh Zadeh (13) , Frédéric Dhermain (14) , Michael Weller (1) , Karl-Josef Langen (2, 15) , Jörg Tonn (5, 16, 17)

1 University Hospital of Cologne [Cologne]
2 Research Center Juelich [Juelich, Germany]
3 University of Cologne
4 Universität Bonn = University of Bonn
5 LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
6 University hospital of Zurich [Zurich]
7 Aarhus University Hospital
8 University Hospital Freiburg
9 ITU - IT University of Copenhagen
10 Medizinische Universität Wien = Medical University of Vienna
11 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
12 Cleveland Clinic
13 Toronto Western Hospital
14 IGR - Institut Gustave Roussy
15 UKA - Universitätsklinikum RWTH Aachen - University Hospital Aachen [Aachen, Germany]
16 Partner Sites - German Cancer Consortium [Freiburg, Germany]
17 Partner Sites - German Cancer Consortium [Munich, Germany]

Meningiomas are the most frequent nonglial primary brain tumors and represent about 30% of brain tumors. Usually, diagnosis and treatment planning are based on neuroimaging using mainly MRI or, rarely, CT. Most common treatment options are neurosurgical resection and radiotherapy (eg, radiosurgery, external fractionated radiotherapy). For follow-up after treatment, a structural imaging technique such as MRI or CT is used. However, these structural imaging modalities have limitations, particularly in terms of tumor delineation as well as diagnosis of posttherapeutic reactive changes. Molecular imaging techniques such as PET can characterize specific metabolic and cellular features which may provide clinically relevant information beyond that obtained from structural MR or CT imaging alone. Currently, the use of PET in meningioma patients is steadily increasing. In the present article, we provide recommendations for the use of PET imaging in the clinical management of meningiomas based on evidence generated from studies being validated by histology or clinical course.

Mots clés: MRI; ligand; meningiomas; positron emission tomography; somatostatin

Domaines: Sciences du Vivant [q-bio]

Norbert Galldiks, Nathalie Albert, Michael Sommerauer, Anca Grosu, Ute Ganswindt, et al.. PET imaging in patients with meningioma—report of the RANO/PET Group. Neuro-Oncology, 2017, 19 (12), pp.1576-1587. ⟨10.1093/neuonc/nox112⟩. ⟨inserm-02940559⟩